Benzinga | Jun 29, 2021 07:54AM EDT

Oppenheimer Maintains Perform on Intellia Therapeutics, Raises Price Target to $125

Oppenheimer analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Perform and raises the price target from $73 to $125.